Navigation Links
Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer

TAMPA, Fla. (Sept. 15, 2011) For patients with ovarian cancer and their physicians, resistance to chemotherapy is a serious concern. However, researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution of chemotherapy resistance. They are hopeful that the discovery may lead to therapies that are tailored to individual patients with ovarian cancer; reversing resistance to chemotherapy and improving survival from the disease.

"Few clinical or biologic events affect survival for patients with ovarian cancer more than the way their tumors respond to chemotherapy," said Johnathan Lancaster, M.D., Ph.D., senior author on a study into chemotherapy resistance recently published in the journal Clinical Cancer Research (17:00, 2011). "We identified a pathway called the 'BCL2 antagonist of cell death,' or BAD, and determined that the activity of the BAD pathway may have more influence on survival than the volume of residual disease after primary surgery."

According to Lancaster and colleagues, the discovery of BAD opens the door to using the pathway as a biomarker to identify patients with the highest-risk ovarian cancer, which are genetically programmed to be resistant to chemotherapy; enabling physicians to identify patients who might benefit from drugs that inhibit the BAD pathway such that chemo-resistance is reversed.

"Targeted therapies that increase a tumor's sensitivity to chemotherapy offer the potential to improve patient survival," explained Lancaster, chair of the Department of Women's Oncology and director of the Center for Women's Oncology at Moffitt.

By treating ovarian cancer cells in a test tube (in vitro) with a chemotherapy drug and observing which genetic pathways became most active, the researchers identified the BAD pathway. To further analyze the activity of the BAD pathway and levels of the BAD protein, the researchers examined tumor specimens and genomic information from almost 300 patients with advanced ovarian cancer. A 47-gene BAD pathway signature was developed and was found to be associated with survival. Subsequent in vitro tests on ovarian cancer cells suggest that it may be possible to inhibit the BAD pathway and reverse resistance to chemotherapy.

"Intriguingly, patients who had lots of cancer remaining at the conclusion of their surgery but whose tumors had low levels of pBAD protein, had better survival than patients with very little cancer remaining following surgery, but who had high levels of pBAD protein," said Lancaster. "Although our data highlights the importance of this newly identified pathway, not all cell line samples showed associations between chemotherapy resistance and BAD pathway genes. There are likely many other pathways and processes contributing to chemotherapy resistance."

The researchers concluded that although more research is necessary, BAD pathway-based biomarkers could open the door to personalized treatment for ovarian cancer by placing women in high-risk and low-risk groups based on their genetic profile for the BAD pathway and protein. Treatments could be selected for each patient according to the status of their BAD pathway.


Contact: Ferdie De Vega
H. Lee Moffitt Cancer Center & Research Institute

Related medicine news :

1. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
2. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
3. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
4. $1.1 million grant targets disparities among medical researchers
5. Yale researchers use uterine stem cells to treat diabetes
6. Clemson researchers using interactive vision tool for driving studies
7. Researchers utilize neuroimaging to show how brain uses objects to recognize scenes
8. Researchers focus on secondary stroke prevention after study reveals room for improvement
9. Researchers find process that clears cholesterol and could reverse major cause of heart attack
10. Aerobic exercise may reduce the risk of dementia, Mayo Clinic researchers say
11. MU researchers use new video gaming technology to detect illness, prevent falls in older adults
Post Your Comments:
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology: